Ranasinghe S, Soghoian DZ, Lindqvist M, Ghebremichael M, Donaghey F, Carrington M, Seaman MS, Kaufmann DE, Walker BD, Porichis F. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses. J. Virol. 2015, 90(5):2208-20.
Osuna CE, Lim SY, Deleage C, Griffin BD, Stein D, Schroeder LT, Omange RW, Best K, Luo M, Hraber PT, Andersen-Elyard H, Ojeda EF, Huang S, Vanlandingham DL, Higgs S, Perelson AS, Estes JD, Safronetz D, Lewis MG, Whitney JB. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat Med. 2016 Dec;22(12):1448-1455. doi: 10.1038/nm.4206. Epub 2016 Oct 3. Erratum in: Nat Med. 2017 Feb 7;23 (2):264. PMID: 27694931; PMCID: PMC5293594.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific anti-HIV Antibodies with Enhanced Breadth and Potency. Cell. 2016, 165(7):1609-20.
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016, 20;352(6288):997-1001.
Lesbats P, Engelman AN, Cherepanov P. Retroviral DNA integration. Chem Rev 2016;116(20):12730-57. doi: 10.1021/acs.chemrev.6B00125. Epub 2016 May 20. PubMed PMID: 27198982; PubMed Central PMCID: PMC5084067.
Stephenson KE, Barouch DH. Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7. doi: 10.1007/s11904-016-0299-7. Review. PubMed PMID: 26841901; PubMed Central PMCID: PMC4779134.
Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O’Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 2016 Nov 15;45(5):1108-1121.
Saito A, Ferhadian D, Sowd GA, Serrao E, Shi J, Halambage UD, Teng S, Soto J, Siddiqui MA, Engelman AN, Aiken C, Yamashita M. Roles of capsid-interacting host factors in multimodal inhibition of HIV-1 by PF74. J Virol 2016 May 27;90(12):5808-23. doi: 10.1128/JVI.03116-15. Print 2016 Jun 15. PubMed PMID: 27076642; PubMed Central PMCID: PMC4886767.
Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, Engelman AN. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc Natl Acad Sci U S A 2016 Feb 23;113(8):E1054-63. doi: 10.1073/pnas.1524213113. Epub 2016 Feb 8. PubMed PMID: 26858452; PubMed Central PMCID: PMC4776470.
Saito A, Henning MS, Serrao E, Dubose BN, Teng S, Huang J, Li X, Saito N, Roy SP, Siddiqui MA, Ahn J, Tsuji M, Hatziioannou T, Engelman AN, Yamashita M. Capsid-CPSF6 interaction is dispensable for HIV-1 replication in primary cells but is selected during virus passage in vivo. J Virol 2016 Jul 11;90(15):6918-35. doi: 10.1128/JVI.00019-16. Print 2016 Aug 1. PubMed PMID: 27307565; PubMed Central PMCID: PMC4944271.
3 Blackfan Circle
Boston, MA 02115 – USA
T 617.667.7000
F 617.735.4566
E CVVRcontact@bidmc.harvard.edu
T 617.735.4610
E CVVRtrials@bidmc.harvard.edu
[DISPLAY_ULTIMATE_SOCIAL_ICONS]